Constitutive activation of alternative nuclear factor kappa B pathway in canine diffuse large B-cell lymphoma contributes to tumor cell survival and is a target of new adjuvant therapies

Davis M. Seelig, Daisuke Ito, Colleen L. Forster, Una A. Yoon, Matthew Breen, Linda J. Burns, Veronika Bachanova, Kerstin Lindblad-Toh, Timothy D. O’Brien, Stephen C. Schmechel, Anthony E. Rizzardi, Jaime F. Modiano, Michael A. Linden

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Activation of the classical nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) pathway is a common molecular event observed in both human and canine diffuse large B-cell lymphoma (DLBCL). Although the oncogenic potential of the alternative NFκB pathway (ANFκBP) has also been recently identified in DLBCL, its precise role in tumor pathogenesis and potential as a treatment target is understudied. We hypothesized that up-regulation of the ANFκBP plays an important role in the proliferation and survival of canine DLBCL cells, and we demonstrate that the ANFκBP is constitutively active in primary canine DLBCL samples and a cell line (CLBL1). We further demonstrate that a small interfering RNA inhibits the activation of the NFκB pathway and induces apoptosis in canine DLBCL cells. In conclusion, the ANFκBP facilitates survival of canine DLBCL cells, and thus, dogs with spontaneous DLBCL can provide a useful large animal model to study therapies targeting the ANFκBP.

Original languageEnglish (US)
Pages (from-to)1702-1710
Number of pages9
JournalLeukemia and Lymphoma
Volume58
Issue number7
DOIs
StatePublished - Jul 3 2017

Fingerprint

Lymphoma, Large B-Cell, Diffuse
NF-kappa B
Canidae
Cell Survival
Neoplasms
Therapeutics
Complementary Therapies
Small Interfering RNA
B-Lymphocytes
Up-Regulation
Animal Models
Dogs
Apoptosis
Light
Cell Line

Keywords

  • Diffuse large B-cell lymphoma
  • alternative NFκB pathway
  • canine model
  • comparative pathology
  • targeting therapy

PubMed: MeSH publication types

  • Journal Article
  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

Cite this

Constitutive activation of alternative nuclear factor kappa B pathway in canine diffuse large B-cell lymphoma contributes to tumor cell survival and is a target of new adjuvant therapies. / Seelig, Davis M.; Ito, Daisuke; Forster, Colleen L.; Yoon, Una A.; Breen, Matthew; Burns, Linda J.; Bachanova, Veronika; Lindblad-Toh, Kerstin; O’Brien, Timothy D.; Schmechel, Stephen C.; Rizzardi, Anthony E.; Modiano, Jaime F.; Linden, Michael A.

In: Leukemia and Lymphoma, Vol. 58, No. 7, 03.07.2017, p. 1702-1710.

Research output: Contribution to journalArticle

@article{1dad189c1da74b8faebdd0fd10fc27b1,
title = "Constitutive activation of alternative nuclear factor kappa B pathway in canine diffuse large B-cell lymphoma contributes to tumor cell survival and is a target of new adjuvant therapies",
abstract = "Activation of the classical nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) pathway is a common molecular event observed in both human and canine diffuse large B-cell lymphoma (DLBCL). Although the oncogenic potential of the alternative NFκB pathway (ANFκBP) has also been recently identified in DLBCL, its precise role in tumor pathogenesis and potential as a treatment target is understudied. We hypothesized that up-regulation of the ANFκBP plays an important role in the proliferation and survival of canine DLBCL cells, and we demonstrate that the ANFκBP is constitutively active in primary canine DLBCL samples and a cell line (CLBL1). We further demonstrate that a small interfering RNA inhibits the activation of the NFκB pathway and induces apoptosis in canine DLBCL cells. In conclusion, the ANFκBP facilitates survival of canine DLBCL cells, and thus, dogs with spontaneous DLBCL can provide a useful large animal model to study therapies targeting the ANFκBP.",
keywords = "Diffuse large B-cell lymphoma, alternative NFκB pathway, canine model, comparative pathology, targeting therapy",
author = "Seelig, {Davis M.} and Daisuke Ito and Forster, {Colleen L.} and Yoon, {Una A.} and Matthew Breen and Burns, {Linda J.} and Veronika Bachanova and Kerstin Lindblad-Toh and O’Brien, {Timothy D.} and Schmechel, {Stephen C.} and Rizzardi, {Anthony E.} and Modiano, {Jaime F.} and Linden, {Michael A.}",
year = "2017",
month = "7",
day = "3",
doi = "10.1080/10428194.2016.1260122",
language = "English (US)",
volume = "58",
pages = "1702--1710",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - Constitutive activation of alternative nuclear factor kappa B pathway in canine diffuse large B-cell lymphoma contributes to tumor cell survival and is a target of new adjuvant therapies

AU - Seelig, Davis M.

AU - Ito, Daisuke

AU - Forster, Colleen L.

AU - Yoon, Una A.

AU - Breen, Matthew

AU - Burns, Linda J.

AU - Bachanova, Veronika

AU - Lindblad-Toh, Kerstin

AU - O’Brien, Timothy D.

AU - Schmechel, Stephen C.

AU - Rizzardi, Anthony E.

AU - Modiano, Jaime F.

AU - Linden, Michael A.

PY - 2017/7/3

Y1 - 2017/7/3

N2 - Activation of the classical nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) pathway is a common molecular event observed in both human and canine diffuse large B-cell lymphoma (DLBCL). Although the oncogenic potential of the alternative NFκB pathway (ANFκBP) has also been recently identified in DLBCL, its precise role in tumor pathogenesis and potential as a treatment target is understudied. We hypothesized that up-regulation of the ANFκBP plays an important role in the proliferation and survival of canine DLBCL cells, and we demonstrate that the ANFκBP is constitutively active in primary canine DLBCL samples and a cell line (CLBL1). We further demonstrate that a small interfering RNA inhibits the activation of the NFκB pathway and induces apoptosis in canine DLBCL cells. In conclusion, the ANFκBP facilitates survival of canine DLBCL cells, and thus, dogs with spontaneous DLBCL can provide a useful large animal model to study therapies targeting the ANFκBP.

AB - Activation of the classical nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) pathway is a common molecular event observed in both human and canine diffuse large B-cell lymphoma (DLBCL). Although the oncogenic potential of the alternative NFκB pathway (ANFκBP) has also been recently identified in DLBCL, its precise role in tumor pathogenesis and potential as a treatment target is understudied. We hypothesized that up-regulation of the ANFκBP plays an important role in the proliferation and survival of canine DLBCL cells, and we demonstrate that the ANFκBP is constitutively active in primary canine DLBCL samples and a cell line (CLBL1). We further demonstrate that a small interfering RNA inhibits the activation of the NFκB pathway and induces apoptosis in canine DLBCL cells. In conclusion, the ANFκBP facilitates survival of canine DLBCL cells, and thus, dogs with spontaneous DLBCL can provide a useful large animal model to study therapies targeting the ANFκBP.

KW - Diffuse large B-cell lymphoma

KW - alternative NFκB pathway

KW - canine model

KW - comparative pathology

KW - targeting therapy

UR - http://www.scopus.com/inward/record.url?scp=85003967140&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85003967140&partnerID=8YFLogxK

U2 - 10.1080/10428194.2016.1260122

DO - 10.1080/10428194.2016.1260122

M3 - Article

VL - 58

SP - 1702

EP - 1710

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 7

ER -